Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature

Constantine D. Georgakopoulos, Foteini Tsapardoni, Elli V. Kostopoulou and Olga E. Makri*

Abstract

**Background:** Deferoxamine (DFO) is one of the most commonly used chelation treatments for transfusional hemosiderosis. Pattern dystrophies constitute a distinct entity of retinal disorders that has been occasionally identified in association with deferoxamine.

**Case presentation:** We report two cases of bilateral macular pattern dystrophy in transfusion dependent patients undergoing chronic chelation therapy with deferoxamine due to thalassemias. Our patients were evaluated with multimodal imaging and the results are presented. Both patients had normal cone and rod responses in the full-field electroretinogram and continued the prescribed chelation therapy, after hematology consult. The patients were followed up every 3 months for 2 and 4 years respectively for possible deterioration. Their best corrected visual acuity remained stable with no anatomic change on Optical Coherence Tomography findings.

**Conclusion:** Multimodal imaging of our patients allowed a better evaluation and possibly earlier detection of the DFO-related changes. Screening and close follow up of patients under chronic chelating therapy is important in order to promptly diagnose and manage possible toxicity either with discontinuation of the offending agent or dose modification.

**Keywords:** Deferoxamine, Pattern dystrophy, Thalassemia, Drug toxicity

**Background**

Thalassemias are a group of inherited blood disorders characterized by imbalance in hemoglobin production. Patients with thalassemia require frequent blood transfusions to survive, resulting in iron overload that necessitates chelation therapy [1]. The most commonly used iron chelators are deferoxamine (DFO), deferiprone and deferasirox. Chronic use of chelating agents, especially DFO, may cause ocular toxicity like pigmentary retinopathy or optic neuropathy presenting with color vision abnormalities, night blindness and visual field defects [2]. Early signs indicative of DFO-induced toxicity are opacification and loss of transparency of the retinal pigment epithelium (RPE) and outer retina, which preceed RPE mottling and may involve the papillomacular, peripapillar or paramacular area [3].

We present two patients undergoing chronic chelation therapy due to thalassemias with bilateral macular pattern dystrophy studied through multimodal imaging and we review the existing literature.

**Case presentation**

**Case 1**

A 54 year old Caucasian woman of Greek ancestry presented to the Retina Service of our Department complaining of metamorphopsia and reduced visual acuity in both eyes, gradually worsening over the past four months. Her past medical history revealed that she suffers from beta thalassemia intermedia for which she receives blood transfusion biweekly and chelation therapy for the past 14 years. Her chelation therapy consists of DFO (50 mg/kg 5 times a week by an 8-hourly subcutaneous infusion), as well as deferiprone (50 mg/kg, per os, daily). Ferritin level was within normal limits. The remainder of her medical history included hypothyroidism treated with levothyroxine. No history of color and peripheral vision changes nor hearing impairment was reported. Her past ocular history was unremarkable.

On the initial examination, best corrected visual acuity (BCVA) was 20/25 in the right eye (OD) and 20/22 in
the left eye (OS). Slit lamp biomicroscopy revealed no pathology from the anterior segment and intraocular pressure (IOP) measured by applanation tonometry was 14 mmHg in both eyes (OU). Dilated fundus examination showed a yellowish roundish macular lesion surrounded by RPE changes, as well as angioid streaks emanating from the optic disc sparing the macula in OU (Fig. 1a, b). The retinal vasculature appeared normal.

Spectral-Domain Optical Coherence Tomography (SD-OCT) revealed a subfoveal hyperreflective deposit above the level of the RPE corresponding to the lesion observed fundoscopically (Fig. 2a, b) while mild stippling was noticed in the macular area in fundus autofluorescence (FAF) (Fig. 1c, d). Finally, fluorescein angiography revealed staining of the macular lesion in the late phases of the angiogram (Fig. 1e, f). To evaluate possible DFO retinopathy in this patient, electrophysiology testing, more specifically, full-field electroretinogram (ffERG) and pattern electroretinogram (PERG), was performed. Amplitudes and implicit times for each major waveform component were included. The responses were taken according to the International Society for Clinical Electrophysiology of Vision (ISCEV) [4]. The ERG revealed no abnormal rod and cone responses OU (Fig. 3). Visual field examination, performed by automated perimetry (Humphrey 30–2 SITA-standard, Carl Zeiss Meditec, Dublin, CA) was also normal.

Taking into consideration the normal ffERG and after consultation with her hematologist, it was decided that the patient would remain on the prescribed chelation therapy, due to the severity of her systemic condition. The patient was followed up every 3 months in our department with SD-OCT for possible deterioration. Her BCVA remained stable for the next 2 years, with no anatomic change on OCT findings (Fig. 2c, d).

Case 2
A 63 year old Caucasian woman of Greek ancestry presented to our Retina Service complaining of decreased central vision OU. She had a medical history of sickle beta thalassemia for which she was receiving regular blood transfusions. She was also receiving iron-chelation treatment with DFO (50 mg/kg 5 times a week by an 8-hourly subcutaneous infusion), for the past 25 years. The rest of her medical and her ocular history were unremarkable. The patient did not report any peripheral, night or color vision problems. There was no history of hearing loss. Her BCVA was 20/50 OU. Slit lamp biomicroscopy was normal and IOP was 15 mmHg in OD and 13 mmHg in OS. Dilated fundus examination revealed the presence of a yellow-brown macular lesion OU. The lesion consisted of yellow pigment lines expanding to the perimacular area in a tri-radiating pattern surrounded by areas of granular hyper-pigmented brown material. Fundus autofluorescence revealed hyperfluorescent areas in a butterfly shaped pattern corresponding to the pigment clumping areas seen in fundoscopy OU (Fig. 4a, b). Fluorescein angiography demonstrated a large hypofluorescent, butterfly-shaped macular lesion surrounded by areas of focal hyperfluorescence OU (Fig. 4c, d). Spectral Domain-OCT demonstrated a subfoveal hyperreflective lesion at the level and above the RPE OU (Fig. 4e, f). Electroretinogram showed no abnormal cone and rod responses. Humphrey visual field perimetry using 30–2 SITA-Standard algorithm was within normal limits.

Haematologists were consulted regarding DFO discontinuation but they decided not to make any change in chelation therapy since the risks pertaining to the patient’s underlying disease outweighed the risk of possible visual loss. Therefore, it was decided to follow-up our patient closely every three months. During a 4 years follow-up period BCVA remained stable without any signs of anatomic change as it was demonstrated with repeated OCT examinations (Fig. 4g, h).

Discussion and conclusions
Beta-thalassemia is an autosomal recessive hemoglobinopathy resulting in anemia due to defective beta-chain globin production leading to impaired production of Hb A. Beta-thalassemia major (β-TM) is associated with diminished b-globin production, while beta-thalassemia intermedia (β-TI) is characterized by some degree of b-globin chain production. Patients with β-TI, however, may also need regular blood transfusions. Sickle beta thalassemia is a particular form of sickle cell disease in which an allele for S hemoglobin and an allele for β-TM coexist. These patients may also require chronic blood transfusions depending on the severity of their anemia [5].

A number of ocular abnormalities have been described in patients with β-TM some of which are attributable to the natural course of the disease and the impact of the anemia on ocular tissues, while others are associated with the chronic chelation treatment [6–9]. More precisely, retinal changes present in β-TM are divided in two categories: pseudoxanthoma elasticum (PXE)-like changes that include angioid streaks, peau d’orange like fundus and optic nerve head drusen [10] and non-PXE-like changes such as increased venous tortuosity [11]. Furthermore, in a study of 255 patients with β-TM or β-TI, Barteselli et al. found a 7.5% incidence of pattern dystrophy-like changes [11].

Concerning sickle thalassemia, Aesopos et al. reported a 10% incidence of angioid streaks in a group of 58 cases [12]. Fanny et al., studied 18 patients suffering from sickle beta thalassemia and found that 13 of the patients had sickle cell retinopathy with 3 of them having proliferative disease. It appears that retinopathy in sickle thalassemia shares similar characteristics with sickle cell retinopathy [13].

Due to chronic repeated blood transfusions, these patients tend to accumulate iron in various organs such as liver,
spleen, myocardium and eyes [14]. In order to prevent iron overload and possible iron-induced toxicity, chelating agents responsible for binding and excreting iron excess are administered. [1] Deferoxamine is a widely used iron-chelator available for both intravenous and subcutaneous administration. Deferoxamine related ocular toxicity involves a wide spectrum of ocular abnormalities such as nyctalopia, colour perception anomalies, visual field disturbances, cataract formation, optic neuropathy and pigmentary retinopathy [3]. Deferiprone, which is an alternative
or adjunctive regimen to DFO, is orally administered and can cross the blood-retina barrier. While degeneration of the RPE has been reported to occur under deferiprone [6, 7], newer studies have demonstrated that it can be a retinal protective iron chelator [15–17]. Finally, deferasirox is a newer oral efficient iron chelator without documented retinal penetration, while cases of reversible toxicity have also been reported. [18, 19]

The standard dose of DFO for chronic transfusional hemosiderosis in patients undergoing chronically repeated blood transfusions is 25–50 mg/kg/day, while a dose of 100 mg/kg/day or more is probable of toxicity [20]. It has been proposed that a daily dose of 50 mg/kg is the upper safe limit for ocular toxicity [21]. Moreover, DFO administered intravenously has been found to carry a higher risk of toxicity than the subcutaneous or intramuscular route [22].

Manifestations of DFO-induced retinal toxicity include RPE changes either at the posterior pole or at the periphery of the retina. Fundus autofluorescence examination in 197 patients with β-TM under DFO treatment, showed a 9% incidence of retinal abnormalities, which were classified, based on their severity, as minimal, focal, patchy and speckled [23]. Out of those, eyes with the patchy pattern showed further RPE damage as demonstrated with FAF, whereas patients with the focal and speckled patterns showed little or no change on follow up examinations with FAF. Visual acuity deteriorated in all eyes except from those with minimal FAF changes [23]. Pattern dystrophy-like lesions have also been described in patients undergoing prolonged DFO treatment (Table 1). Reviewing the cases in Table 1 we found 4 published cases of vitelliform maculopathy and 3 cases of butterfly shaped macular lesions associated with DFO in literature [24–26].

The exact mechanism of DFO toxicity, although thoroughly studied, remains unclear. Rahi et al. noticed thickening of Bruch’s membrane and depigmentation and degeneration of the RPE cells in microscopic examination of eyes with DFO retinopathy [27]. Pathophysiology of retinal damage in patients chronically treated with DFO is supposed to occur due to disruption of iron homeostasis in the retina [28] as well as chelation of other metals vital for proper retinal function such as copper, cobalt, zinc and nickel. [29, 30] In addition, DFO has been found to exhibit a direct p38 mediated toxic effect to RPE cells in in vitro studies [31]. In respect to pattern dystrophies in patients receiving DFO, histologic studies are required to elucidate the pathogenetic process of fluorophore buildup between RPE and outer photoreceptor segments that lead to the development of such lesions.

Electrophysiology testing has been proposed as a means for monitoring retinal function in cases of suspected DFO toxicity. Electroretinogram and electrooculogram (EOG) are usually confirmatory of DFO retinopathy and appear to be more sensitive in detecting early retinal damage than fundoscopy alone [3]. A recent study suggests that ffERG and multi-focal ERG are more sensitive in early damage detection than visual evoked potential, FAF imaging and OCT scans in patients under chelation therapy [32]. For instance, there are reports of bilateral reductions in response densities at the central...
retina corresponding to RPE changes related to DFO toxicity [3, 33, 34]. Repeated examinations with multifocal ERG have also been used for the follow up of patients with DFO related maculopathy in order to record functional changes. However, due to lack of specificity of these tests for DFO toxicity, various different results have been presented in literature [33]. Regarding pattern dystrophies, various contradicting electrophysiology findings have been reported in literature (Table 1). More specifically, ERG results range from normal [3, 26] to impaired cone [25] or rod responses [35]. Diffuse dysfunction in EOG has also been reported in one vitelliform case [35]. In our cases, patients had normal cone and rod responses in the full field ERG.

Cessation of DFO treatment has been reported to reverse early DFO toxicity related changes [36]. Kertes et al. however, reported progressive deterioration in mfERG during the first 4 months after discontinuation of DFO, which did not stabilize until 8 months later [37]. Regarding macular pattern-like dystrophies, limited information exists in literature on the possible effect of DFO cessation or DFO dose modification (Table 1). Viola et al. reported switch of chelation treatment, from DFO to deferasirox, in a patient with a vitelliform-like lesion as well as one patient with butterfly shaped macular changes while chelation therapy remained unchanged on two patients with butterfly shaped-like macular changes [24]. Interestingly, progressive RPE atrophy was demonstrated during follow-up in all of the above four patients, although resolution of the hyperreflective material had initially been observed in the patient with the vitelliform-like lesion [24]. In the cases reported by
Gonzales visual deterioration occurred despite DFO discontinuation [25]. Finally, administration of brinzolamide 0.1% in a patient with vitelliform maculopathy related to DFO resulted in reduction of the macular lesion [38]. In a recent case report of a pseudovitelliform maculopathy related to DFO, further deterioration occurred after changing the chelator from DFO to deferasirox [35].

Fig. 4 Butterfly shaped macular dystrophy in a transfusion dependent 63 year old patient receiving deferoxamine chelation therapy due to sickle beta thalassemia (Patient 2). Fundus autofluorescence shows hyperautofluorescence in a branching pattern with some areas of reduced autofluorescence corresponding to the pigment clumping seen in fundoscopy OU (a, b). Fluorescein angiography reveals central hypofluorescence with adjacent areas of focal hyperfluorescence OU, that persists as staining without leakage in the late frames (c, d). Optical coherence tomography at the time of diagnosis showing hyporeflective material in the outer retinal layers, located at the level and above the RPE in both maculas (e, f). There is evident disruption of the ellipsoid zone by the amorphous material in the left eye. After 4 years, follow up OCT remains unchanged OS while there is a slight increase of the subfoveal debris in OD (g, h).
Table 1: Published pattern dystrophy cases associated with chelation therapy

| Study (Year) | Study type | No of Patients | DFO Treatment | Electrophysiology Tests | Retinal Findings | Additional information | Management | Follow up - outcome |
|--------------|------------|----------------|---------------|--------------------------|------------------|------------------------|------------|---------------------|
| Genead et al. [26] | Case report 1 Case | SQ N/A | ERG normal | Vitelliform Macular Lesion | Splenectomy Mild hearing impairment | N/A regarding chelation therapy Brinzolamide 0.1% initiation | Improvement of vitelliform lesion in one eye with Brinzolamide 0.1% drops |
| Gonzales et al. [25] | Case series 2 Patients | PT1 1 g/2daily/SQ for 11 months, PT2 IV 2680 mg/5x weekly for 3 years | PT1 ERG, EOG normal PT2 ERG reduction in cone mediated responses EOG normal | Vitelliform Macular Lesion | Myelodysplasia | PT1 initially DFO dose reduced to 500 mg/day SQ, at 4 months increased to 1 g/d, discontinued at 1 year PT2 DFO discontinuation | PT1 Vision deteriorated, vitelliform lesion increased and atrophy developed at 2 years follow up, inspite of DFO dose modification and final discontinuation PT2 Vision deteriorated at 1 year follow up Lesion anatomically unchanged in one eye, resolution of vitelliform lesion in the fellow eye |
| Viola et al. [24] | Retrospective Chart Review Study 20/290 | SQ Range 1.5–4.5 mg/kg Mean 32.7 ± 8.7 years Range 20–52 years | N/A | Butterfly shaped macular lesion [3] Vitelliform macular lesion [1] Fundus flavimaculatus-like [3] Fundus pulvinulentus-like [3] Minimal change [10] | Beta-thalassemia | Vitelliform PT switched to deferasirox 1 butterfly PT switched to deferasirox, 2 unchanged | Mean duration of follow up 19.7 ± 8.8 months (range 10–45 months). 6 patients (one with Butterfly shaped and one with Vitelliform-like macular lesion) switched to deferasirox 14 patients remained on the same chelation regimen All Butterfly shaped and Vitelliform cases progressed to RPE atrophy during follow up |
| Bui et al. [35] | Case report 1 Case | N/A 16 g/week for 5 years | ERG diffuse rod dysfunction in one eye diffuse dysfunction in EOG in both eyes | Vitelliform Macular Lesion | Myelodysplasia Adult onset hearing loss | DFO discontinuation Switch to deferasirox Brinzolamide 0.1% initiation | Lesion reduced in size 2 months after DFO discontinuation then increased on deferasirox Vision remained stable PT lost on follow up |

Abbreviations used: DFO deferoxamine, SQ subcutaneous, ERG electoretinogram, EOG electrooculogram, PT patient, N/A not available
In this report, we present two cases of relatively rare pattern dystrophy like macular changes in patients treated with DFO for a prolonged period of time. Multimodal imaging utilization in our patients allowed a better evaluation and possibly earlier detection of the DFO-related changes. The correlation between DFO and the retinal changes presented in our patients is enhanced by the absence of any family history of macular pathology, the chronic treatment with DFO and the symmetric and bilateral appearance of macular changes. The age of presentation of visual disturbances in both patients is the 5th and 6th decade of life respectively, which also favors the diagnosis of an adult onset macular dystrophy. However, exclusion of possible genetic defects would further support the conclusion of an acquired pattern dystrophy of the macula induced by desferrioxamine. Adjustment of chelation treatment could have been a more proactive approach. However, in our cases, haematologist consultation suggested that patients should remain on the prescribed chelation therapy and be closely followed-up every three months. No sign of deterioration was observed over a period of 2 and 4 years respectively. Screening is therefore important for early detection, prompt diagnosis and follow up of possible drug-related toxicity in this particular group of patients.

**Abbreviations**

BCVA: best-corrected visual acuity; DFO: deferoxamine; EOG: electrooculogram; FAF: fundus autofluorescence; fERG: full-field electroretinogram; IOP: intraocular pressure; OD: right eye; OS: left eye; OU: both eyes; PXE: pseudoxanthoma elasticum; RPE: retinal pigment epithelium; SD-OCT: Spectral-Domain Optical Coherence Tomography; β-TI: beta-thalassemia intermedia; β-TM: Beta-thalassemia major

**Declarations**

**Availability of data and materials**

All the data supporting our findings is contained within the manuscript.

**Authors’ contributions**

CG participated in diagnosis and treatment of the patient, drafted the manuscript, reviewed the literature and critically revised the manuscript for important intellectual content. FT helped to draft the manuscript and participated in the literature search and information gathering. EK helped to draft the manuscript, participated in the literature search and information gathering. OM participated in diagnosis and treatment of the patient, drafted the manuscript, collected the data and reviewed the literature. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The approval and consent to participate was not required as the data of the case report has been analyzed in a retrospective manner and has no effect on treatment of the patient.

**Consent for publication**

Written informed consent was obtained from the patients for publication of this case report and the accompanying images. A copy of the consents is available for review by the Editor of this journal.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364:146–56.
2. Lakanpal V, Schocket SS, Ji Ji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology. 1981;94:431–4.
3. Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology. 2002;109:64–71.
4. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigg M, Bach M. ISCEV standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol. 2009;118:69–77.
5. Yawn BP, Buchanan GR, Afenyo-Annan AN, Blass SK, Hassell KL, James AH, Jordan L, Landtorn SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sohaw J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033–48.
6. Tafer A, Badshur Z, Shamsseddine WA, Abdulnour RE, Aoun E, Koussa S, Baz P. Ocular findings among thalassemia patients. Am J Ophthalmol. 2006;142:704–5.
7. Taneja R, Malik P, Sharma M, Azanval MC. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population. Indian J Ophthalmol. 2010;58:125–30.
8. De Virgiliis S, Congia M, Turco MF, Frau F, Dessi C, Arcioli F, Sorcinelli R, Stitza A, Cao A. Depletion of trace elements and acute ocular toxicity induced by deferoxamine in patients with thalassemia. Arch Dis Child. 1984;63(3):250–5.
9. Arora A, Wren S, Gregory Evans K. Desferrioxamine related maculopathy: a case report. Am J Hematol. 2004;76:386–8.
10. Aessopos A, Savvides P, Stamatoles G, et al. Pseudoxanthoma elasticum-like skin lesions and angioid streaks in beta-thalassemia. Am J Hematol. 1992;41:159–64.
11. Barteselli G, Del Fanti L, FINGER RP, Charbel Issa P, Marcon A, Vezzola D, Mapelli C, Cassiniero E, Cappelli MD, Ratiq G, Volta F. The spectrum of ocular alterations in patients with beta-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum. Ophthalmology. 2014;121:709–18.
12. Aessopos A, Voskaridou E, Vassilopoulos G, Rombos Y, Gavriel L, Loukopoulos D. Angioid streaks in sickle-thalassemia. Am J Ophthalmol. 1994;117:589–92.
13. Fanny A, Coulibaly F, Gbe K, Mette M, Adjorlolo C, Konan-Toure ML, Berete R, Boni S, Ouattara A, Diao M. Sickle cell beta-thalassemia leading to serious ischemic retinopathy: a study of 18 patients in Abidjan. J Fr Ophtalmol. 2005;28:391–5.
14. Bonkovsky HL, Davidoff A, Stark DD. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:1653. author reply 1657.
15. Hadzialahmetovic M, Pajic M, Grcic S, Song Y, Song D, Li Y, Cwanger A, Iacovelli J, Chu S, Ying G, Connelly J, Spino M, Dunai J. The oral iron Chelator Deferiprone protects against retinal degeneration induced through diverse mechanisms. Trans Vis Sci Technol. 2012;1:7.
16. Song D, Song Y, Hadzialahmetovic M, Zhong Y, Dunai J. Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina. Free Radic Biol Med. 2012;53:64–71.
17. Song D, Zhao L, Li Y, Hadzialahmetovic M, Song Y, Connelly J, Spino M, Dunai J. The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice. Invest Ophthalmol Vis Sci. 2014;55:4525–32.
18. Pan Y, Keane PA, Sadun AA, Faawy AA. Optical coherence tomography findings in deferasirox-related maculopathy. Retin Cases Brief Rep. 2010;4:229–32.
19. Walia HS, Yan J. Reversible retinopathy associated with oral deferasirox therapy. BMJ Case Rep. 2013; 2013. pii: bcr2013009205.

**Consent for publication**

Written informed consent was obtained from the patients for publication of this case report and the accompanying images. A copy of the consents is available for review by the Editor of this journal.
20. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2:181–4.

21. Cohen A, Martin M, Mizanin J, et al. Vision and hearing during deferoxamine therapy. J Pediatr. 1990;117:326–30.

22. Baath JS, Lam WC, Kirby M, Chun A. Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population. Retina. 2008;28:894–9.

23. Viola F, Baresielli G, Dell’Arti L, Vezzola D, Villani E, Mapelli C, Zanaboni L, Cappellini MD, Ratiglia R. Abnormal fundus autofluorescence results of patients in long-term treatment with deferoxamine. Ophthalmology. 2012;119:1693–700.

24. Viola F, Baresielli G, Dell’Arti L, Vezzola D, Mapelli C, Villani E, Ratiglia R. Multimodal imaging in deferoxamine retinopathy. Retina. 2014;34:1428–38.

25. Gonzales CR, Lin AP, Engstrom RF, Kreiger AE. Bilateral vitelliform maculopathy and deferoxamine toxicity. Retina. 2004;24:464–7.

26. Genead MA, Fishman GA, Anastasakis A, Lindeman M. Macular vitelliform lesion in deferoxamine-related retinopathy. Doc Ophthalmol. 2010;121:161–6.

27. Rahi AH, Hungerford JL, Ahmed AI. Ocular toxicity of deferoxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol. 1986;70:373–81.

28. Reddy S, Iturralde D, Meyerle C, Gross NE, Yannuzzi LA. Fundus autofluorescence in retinopathy caused by deferoxamine toxicity. Retin Cases Brief Rep. 2007;1:120–2.

29. Pall H, Blake DR, Winyard P, Lunec J, Williams A, Good PA, Kritzinger EE, Cornish A, Hider RC. Ocular toxicity of deferoxamine—an example of copper promoted auto-oxidative damage? Br J Ophthalmol. 1989;73:42–7.

30. Chaston TB, Richardson DR. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity. Am J Hematol. 2003;73:200–10.

31. Klettner A, Konzer S, Waetzig V, Herdegen T, Roeder J. Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38. Curr Opin Toxicol. 2010;3:122–9.

32. Dettori M, Kattamis A, Ladas I, Maragkos K, Koutsandrea C, Chatzistefanou K, Laios K, Brouzas D, Moschos MM. Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients. Graefes Arch Clin Exp Ophthalmol. 2017;255:1349–58.

33. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol. 1986;70:373–81.

34. Jiang C, Hansen RM, Gee BE, Kerkh SS, Fulton AB. Rod and rod mediated function in patients with beta-thalassemia major. Doc Ophthalmol. 1999;99:333–45.

35. Bui RM, Sadda SR, Salehi-Had H. Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity. Digit J Ophthalmol. 2017;23:11–5.

36. Roulez F. Retinal pigment epithelium-desferal. Bull Soc Belge Ophthalmol. 2007;304:69–66.

37. Kertes PJ, Lee TK, Coupland SG. The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy. Can J Ophthalmol. 2004;39:556–61.

38. Genead MA, Fishman GA. Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy. Ophthalmic Surg Lasers Imaging 2011;42; e114–e117. Online.